<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFOTETAN- cefotetan disodium injection, powder, for solution </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1>Cefotetan for Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="dd2919cf-9af3-4530-88ef-cbab8aaaee2e"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx only</p>
<p><span class="Bold"><span class="Emphasis">      For Intravenous Use Only</span></span></p>
<br><table>
<colgroup><col align="left"></colgroup>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold"><span class="Emphasis">PHARMACY BULK PACKAGE -</span></span><p class="First"><span class="Bold"><span class="Emphasis">NOT FOR DIRECT INFUSION</span></span></p>
<br>
</td></tr></tbody>
</table>
<br><p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotetan and other antibacterial drugs, cefotetan should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="f7b9edcb-4b8b-47df-b9ff-8691ecdd9c08"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cefotetan for Injection, USP, as cefotetan disodium, is a sterile, semisynthetic, broad-spectrum, beta-lactamase resistant, cephalosporin (cephamycin) antibiotic for parenteral administration.  It is the disodium salt of [6<span class="Italics"><span class="Emphasis">R</span></span>-(6α,7α)]-7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1<span class="Italics"><span class="Emphasis">H</span></span>-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.  Structural formula: </p>
<p><img alt="structue" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6b8667e-8bb6-ea58-a969-2f74458bc611&amp;name=cefotetan-for-injection,-usp-figure-1-cefotetan-structure.jpg"> </p>
<p>Cefotetan for Injection, USP is supplied in a Pharmacy Bulk Package containing 80 mg (3.5 mEq) of sodium per gram of cefotetan activity.  It is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder which is very soluble in water.  Reconstituted solutions of Cefotetan for Injection, USP are intended for intravenous administration.  The solution varies from colorless to yellow depending on the concentration.  The pH of freshly reconstituted solutions is usually between 4.5 to 6.5. </p>
<p>Each Cefotetan for Injection Pharmacy Bulk Package bottle is supplied as a dry powder containing sterile cefotetan disodium equivalent to 10 grams cefotetan and is intended for intravenous use only.  Cefotetan for Injection, USP contains 80 mg (3.5 mEq) of sodium per gram of cefotetan activity.</p>
<p>A Pharmacy Bulk Package is a container of sterile preparation for parenteral use that contains many single doses.  The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.  FURTHER DILUTION IS REQUIRED BEFORE USE (see <span class="Bold"><span class="Emphasis"><a href="#b58ac185-b10f-4d2d-bea0-83e1d8c4d5cf">DOSAGE AND ADMINISTRATION,</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#b58ac185-b10f-4d2d-bea0-83e1d8c4d5cf">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="a48fde80-c849-4413-971c-b65209ef0429"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">High plasma levels of cefotetan are attained after intravenous administration of single doses to normal volunteers.</p>
<table><tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="8">
<p class="First"><span class="Bold"><span class="Emphasis">PLASMA CONCENTRATIONS AFTER 1 GRAM IV<span class="Sup">a</span> OR IM DOSE</span></span></p>
<p><span class="Bold"><span class="Emphasis">                      Mean Plasma Concentration (mcg/mL)</span></span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="8">
<span class="Bold"><span class="Emphasis">                                     Time After Injection</span></span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Route</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">15 min</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">30 min</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">1 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">2 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">4 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">8 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">12 h</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">IV</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">92</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">158</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">103</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">72</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">IM</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">34</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">56</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">71</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">68</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">47</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="8" valign="top"><p class="First"><span class="Sup">a</span> 30-minute infusion</p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="8">
<p class="First"><span class="Bold"><span class="Emphasis">PLASMA CONCENTRATIONS AFTER 2 GRAM IV<span class="Sup">a</span> OR IM DOSE</span></span></p>
<p><span class="Bold"><span class="Emphasis">                        Mean Plasma Concentration (mcg/mL)</span></span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="8">
<span class="Bold"><span class="Emphasis">                                    Time After Injection</span></span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Route</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">5 min</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">10 min</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">1 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">3 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">5 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">9 h</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">12 h</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">IV</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">237</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">223</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">135</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">74</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">48</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12<span class="Sup">b</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">IM</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">—</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">75</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">91</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">69</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">19</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="8" valign="top"><p class="First"><span class="Sup">a</span> Injected over 3 minutes </p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="8" valign="top"><p class="First"><span class="Sup">b</span> Concentrations estimated from regression line </p></td></tr>
</tbody></table>
<br><p>The plasma elimination half-life of cefotetan is 3 to 4.6 hours after intravenous administration.</p>
<p>Repeated administration of cefotetan does not result in accumulation of the drug in normal subjects.</p>
<p>Cefotetan is 88% plasma protein bound.</p>
<p>No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.</p>
<p>In normal patients, from 51% to 81% of an administered dose of cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.  Following intravenous doses of 1 gram and 2 grams, urinary concentrations are highest during the first hour and reach concentrations of approximately 1700 and 3500 mcg/mL, respectively.</p>
<p>In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged.  The mean terminal half-life increases with declining renal function, from approximately 4 hours in volunteers with normal renal function to about 10 hours in those with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  There is a linear correlation between the systemic clearance of cefotetan and creatinine clearance.  When renal function is impaired, a reduced dosing schedule based on creatinine clearance must be used (see <span class="Bold"><span class="Emphasis"><a href="#b58ac185-b10f-4d2d-bea0-83e1d8c4d5cf"> DOSAGE AND ADMINISTRATION</a></span></span>). </p>
<p>In pharmacokinetic studies of eight elderly patients (greater than 65 years) with normal renal function and six healthy volunteers (aged 25 to 28 years), mean (± 1 sd) Total Body Clearance (1.8 (0.1) L/h vs. 1.8 (0.3) L/h) and mean Volume of Distribution (10.4 (1.2) L vs. 10.3 (1.6) L) were similar following administration of a one gram intravenous bolus dose.</p>
<p>Therapeutic levels of cefotetan are achieved in many body tissues and fluids including: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">skin</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">ureter</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">muscle</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">bladder</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">fat</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">maxillary sinus mucosa</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">myometrium       </p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">tonsil</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">endometrium</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">bile</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">cervix</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">peritoneal fluid</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">ovary</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">umbilical cord serum</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">kidney</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">amniotic fluid</p></td>
</tr>
</tbody></table>
<div class="Section" data-sectionCode="34090-1">
<a name="eaa8ec7a-1733-4557-834d-0a44bf2c4845"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The bactericidal action of cefotetan results from inhibition of cell wall synthesis.  Cefotetan has <span class="Italics"><span class="Emphasis">in vitro</span></span> activity against a wide range of aerobic and anaerobic gram-positive and gram-negative organisms.  The methoxy group in the 7-alpha position provides cefotetan with a high degree of stability in the presence of beta-lactamases including both penicillinases and cephalosporinase of gram-negative bacteria.  </p>
<p>Cefotetan has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms <span class="Bold"><span class="Emphasis">both </span></span><span class="Bold Italics"><span class="Emphasis">in vitro</span></span><span class="Bold"><span class="Emphasis"> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </span></span>(see<span class="Bold"><span class="Emphasis"><a href="#bbaee93a-54fc-4cd9-b563-9abc481871d4"> INDICATIONS AND USAGE</a></span></span>).</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Gram-Negative Aerobes    </span></span></p>
<p><span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">          Escherichia coli         </span></span><br></span></span></p>
<p><span class="Italics"><span class="Emphasis">      Haemophilus influenzae    </span></span> (including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics"><span class="Emphasis">      Klebsiella    </span></span> species (including <span class="Italics"><span class="Emphasis">K. pneumoniae</span></span>)</p>
<p><span class="Italics"><span class="Emphasis">      Morganella morganii    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Neisseria gonorrhoeae     </span></span>(nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics"><span class="Emphasis">      Proteus mirabilis    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Proteus vulgaris    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Providencia rettgeri    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Serratia marcescens    </span></span></p>
<p><span class="Bold"><span class="Emphasis">      NOTE    </span></span>: Approximately one-half of the usually clinically significant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Enterobacter</span></span> species (e.g., <span class="Italics"><span class="Emphasis">E. aerogenes</span></span> and <span class="Italics"><span class="Emphasis">E. cloacae</span></span>) are resistant to cefotetan.  Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Pseudomonas aeruginosa</span></span> and <span class="Italics"><span class="Emphasis">Acinetobacter</span></span> species are resistant to cefotetan. </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Gram-Positive Aerobes    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Staphylococcus aureus    </span></span> (including penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) </p>
<p><span class="Italics"><span class="Emphasis">      Staphylococcus epidermidis     </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Streptococcus agalactiae    </span></span> (group B beta-hemolytic streptococcus) </p>
<p><span class="Italics"><span class="Emphasis">      Streptococcus pneumoniae     </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Streptococcus pyogenes     </span></span></p>
<p><span class="Bold"><span class="Emphasis">      NOTE    </span></span>: Methicillin-resistant staphylococci are resistant to cephalosporins.  Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Staphylococcus epidermidis</span></span> and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci, e.g., <span class="Italics"><span class="Emphasis">Enterococcus faecalis</span></span> (formerly <span class="Italics"><span class="Emphasis">Streptococcus faecalis</span></span>) are resistant to cefotetan.  </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Anaerobes    </span></span><span class="Italics"><span class="Emphasis"><br></span></span></p>
<p><span class="Italics"><span class="Emphasis">      Prevotella bivia    </span></span> (formerly <span class="Italics"><span class="Emphasis">Bacteroides bivius</span></span>) </p>
<p><span class="Italics"><span class="Emphasis">      Prevotella disiens    </span></span> (formerly <span class="Italics"><span class="Emphasis">Bacteroides disiens</span></span>)</p>
<p><span class="Italics"><span class="Emphasis">      Bacteroides fragilis     </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Prevotella melaninogenica    </span></span> (formerly <span class="Italics"><span class="Emphasis">Bacteroides melaninogenicus</span></span>)</p>
<p><span class="Italics"><span class="Emphasis">      Bacteroides vulgatus     </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Fusobacterium    </span></span> species</p>
<p>Gram-positive bacilli (including <span class="Italics"><span class="Emphasis">Clostridium</span></span> species; see <span class="Bold"><span class="Emphasis"><a href="#a28ba117-1bb6-40b1-ba61-870da1eb3f00"> WARNINGS</a></span></span>)</p>
<p>NOTE: Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">C. difficile</span></span> are resistant (see <span class="Bold"><span class="Emphasis"><a href="#a28ba117-1bb6-40b1-ba61-870da1eb3f00"> WARNINGS</a></span></span>). </p>
<p><span class="Italics"><span class="Emphasis">      Peptococcus niger    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Peptostreptococcus    </span></span> species</p>
<p><span class="Bold"><span class="Emphasis">      NOTE    </span></span>: Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">B. distasonis</span></span>, <span class="Italics"><span class="Emphasis">B. ovatus</span></span> and <span class="Italics"><span class="Emphasis">B. thetaiotaomicron</span></span> are resistant to cefotetan <span class="Italics"><span class="Emphasis">in</span></span><span class="Italics"><span class="Emphasis"> vitro</span></span>.  However, the therapeutic utility of cefotetan against these organisms cannot be accurately predicted on the basis of <span class="Italics"><span class="Emphasis">in vitro</span></span> susceptibility tests alone.</p>
<p>The following <span class="Italics"><span class="Emphasis">in vitro</span></span> data are available but their clinical significance is unknown.  Cefotetan has been shown to be active <span class="Italics"><span class="Emphasis">in vitro</span></span> against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms:</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Gram-Negative Aerobes    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Citrobacter    </span></span> species (including <span class="Italics"><span class="Emphasis">C. diversus</span></span> and <span class="Italics"><span class="Emphasis">C. freundii</span></span>)</p>
<p><span class="Italics"><span class="Emphasis">      Klebsiella oxytoca     </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Moraxella (Branhamella) catarrhalis     </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Neisseria gonorrhoeae    </span></span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) </p>
<p><span class="Italics"><span class="Emphasis">      <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>    </span></span> species </p>
<p><span class="Italics"><span class="Emphasis">      Serratia    </span></span> species </p>
<p><span class="Italics"><span class="Emphasis">      Shigella    </span></span> species </p>
<p><span class="Italics"><span class="Emphasis">      Yersinia enterocolitica    </span></span></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Anaerobes    </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Porphyromonas asaccharolytica    </span></span> (formerly <span class="Italics"><span class="Emphasis">Bacteroides asaccharolyticus</span></span>)</p>
<p><span class="Italics"><span class="Emphasis">      Prevotella oralis    </span></span> (formerly <span class="Italics"><span class="Emphasis">Bacteroides oralis</span></span>) </p>
<p><span class="Italics"><span class="Emphasis">      Bacteroides splanchnicus     </span></span></p>
<p><span class="Italics"><span class="Emphasis">      Clostridium difficile    </span></span> (see <span class="Bold"><span class="Emphasis"><a href="#a28ba117-1bb6-40b1-ba61-870da1eb3f00"> WARNINGS</a></span></span>) </p>
<p><span class="Italics"><span class="Emphasis">      Propionibacterium    </span></span> species </p>
<p><span class="Italics"><span class="Emphasis">      Veillonella    </span></span>species</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e46aa9be-2b74-474d-aef3-2ab4115ef380"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Tests<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Dilution Techniques</span></span></p>
<p>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs).  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.  The MICs should be determined using a standardized procedure.  Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefotetan powder.  The MIC values should be interpreted according to the following criteria: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">MIC (mcg/mL            )</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Interpretation            </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">≤ 16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">≥ 64</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Resistant (R)</p></td>
</tr>
</tbody></table>
<p>A report of 'Susceptible' indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable.  A report of 'Intermediate' indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.  This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation.  A report of 'Resistant' indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.  Standard cefotetan powder should provide the following MIC values: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Microorganism</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">MIC (mcg/mL)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Italics"><span class="Emphasis">              E. coli             </span></span> ATCC 25922</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.06 to 0.25</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Italics"><span class="Emphasis">              S. aureus             </span></span> ATCC 29213</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4 to 16</p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis">      Diffusion Techniques    </span></span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.  One such standardized procedure<span class="Sup">2</span> requires the use of the standardized inoculum concentrations.  This procedure uses paper disks impregnated with 30 mcg cefotetan to test the susceptibility of microorganisms to cefotetan.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg cefotetan disk should be interpreted according to the following criteria: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Zone Diameter (mm            )</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Interpretation            </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">≥ 16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">13 to 15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">≤ 12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Resistant (R)</p></td>
</tr>
</tbody></table>
<p>Interpretation should be as stated above for results using dilution techniques.  Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefotetan.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures.  For the diffusion technique, the 30 mcg cefotetan disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First">Microorganism </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Zone Diameter (mm)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Italics"><span class="Emphasis">              E. coli             </span></span> ATCC 25922</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">28 to 34</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Italics"><span class="Emphasis">              S. aureus             </span></span> ATCC 25923</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">17 to 23</p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis">      Anaerobic Techniques    </span></span></p>
<p>For anaerobic bacteria, the susceptibility to cefotetan as MICs can be determined by standardized test methods<span class="Sup">3</span>.  The MIC values obtained should be interpreted according to the following criteria: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">MIC (mcg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Interpretation</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">≤ 16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">≥ 64</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Resistant (R)</p></td>
</tr>
</tbody></table>
<p>Interpretation is identical to that stated above for results using dilution techniques.</p>
<p>As with other susceptibility techniques, the use of laboratory control microorganisms is required to control the technical aspects of the laboratory standardized procedures.  Standardized cefotetan powder should provide the following MIC values: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Microorganism            </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">MIC (mcg/mL)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Italics"><span class="Emphasis">              Bacteroides fragilis  </span></span>ATCC 25285</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4 to 16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Italics"><span class="Emphasis">              Bacteroides thetaiotaomicron  </span></span>ATCC 29741</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">32 to 128</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Italics"><span class="Emphasis">              Eubacterium lentum  </span></span>ATCC 43055</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">32 to 128</p></td>
</tr>
</tbody></table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="bbaee93a-54fc-4cd9-b563-9abc481871d4"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotetan and other antibacterial drugs, cefotetan should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<div class="Section" data-sectionCode="34067-9">
<a name="de3ff497-0171-4449-a4f2-5a5fbc0b50bf"></a><a name="section-4.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Cefotetan for Injection, USP is indicated for the therapeutic treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms: </p>
<p><span class="Bold"><span class="Emphasis">      <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>    </span></span> caused by <span class="Italics"><span class="Emphasis">E. coli, Klebsiella</span></span> spp (including <span class="Italics"><span class="Emphasis">K. pneumoniae</span></span>), <span class="Italics"><span class="Emphasis">Proteus mirabilis</span></span> and <span class="Italics"><span class="Emphasis">Proteus</span></span> spp (which may include the organisms now called <span class="Italics"><span class="Emphasis">Proteus </span></span><span class="Italics"><span class="Emphasis">vulgaris</span></span>, <span class="Italics"><span class="Emphasis">Providencia rettgeri</span></span>, and <span class="Italics"><span class="Emphasis">Morganella morganii</span></span>). </p>
<p><span class="Bold"><span class="Emphasis">      <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span>    </span></span> caused by <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span>, <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span> (penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics"><span class="Emphasis">Haemophilus </span></span><span class="Italics"><span class="Emphasis">influenzae</span></span> (including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics"><span class="Emphasis">Klebsiella </span></span>species (including <span class="Italics"><span class="Emphasis">K. pneumoniae</span></span>), <span class="Italics"><span class="Emphasis">E. coli</span></span>, <span class="Italics"><span class="Emphasis">Proteus mirabilis</span></span>, and <span class="Italics"><span class="Emphasis">Serratia marcescens.*</span></span></p>
<p><span class="Bold"><span class="Emphasis">      Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>    </span></span> due to <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span> (penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics"><span class="Emphasis">Staphylococcus epidermidis</span></span>, <span class="Italics"><span class="Emphasis">Streptococcus pyogenes</span></span>, <span class="Italics"><span class="Emphasis">Streptococcus</span></span> species (excluding enterococci), <span class="Italics"><span class="Emphasis">Escherichia coli</span></span>, <span class="Italics"><span class="Emphasis">Klebsiella pneumoniae</span></span>, <span class="Italics"><span class="Emphasis">Peptococcus niger</span></span>*, <span class="Italics"><span class="Emphasis">Peptostreptococcus</span></span> species. </p>
<p><span class="Bold"><span class="Emphasis">      Gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>    </span></span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span> (including penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics"><span class="Emphasis">Staphylococcus epidermidis</span></span>, <span class="Italics"><span class="Emphasis">Streptococcus</span></span> species (excluding enterococci), <span class="Italics"><span class="Emphasis">Streptococcus agalactiae</span></span>, <span class="Italics"><span class="Emphasis">E. coli</span></span>, <span class="Italics"><span class="Emphasis">Proteus mirabilis</span></span>, <span class="Italics"><span class="Emphasis">Neisseria</span></span><span class="Italics"><span class="Emphasis"> gonorrhoeae</span></span>, <span class="Italics"><span class="Emphasis">Bacteroides</span></span> species (excluding <span class="Italics"><span class="Emphasis">B. distasonis</span></span>, <span class="Italics"><span class="Emphasis">B. ovatus</span></span>, <span class="Italics"><span class="Emphasis">B. thetaiotaomicron</span></span>), <span class="Italics"><span class="Emphasis">Fusobacterium</span></span> species*, and gram-positive anaerobic cocci (including <span class="Italics"><span class="Emphasis">Peptococcus </span></span><span class="Italics"><span class="Emphasis">niger</span></span> and <span class="Italics"><span class="Emphasis">Peptostreptococcus</span></span> species).</p>
<p>Cefotetan, like other cephalosporins, has no activity against <span class="Italics"><span class="Emphasis">Chlamydia trachomatis. </span></span> Therefore, when cephalosporins are used in the treatment of <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>, and <span class="Italics"><span class="Emphasis">C. trachomatis</span></span> is one of the suspected pathogens, appropriate antichlamydial coverage should be added. </p>
<p><span class="Bold"><span class="Emphasis">      Intra-abdominal lnfections    </span></span> caused by <span class="Italics"><span class="Emphasis">E. coli</span></span>, <span class="Italics"><span class="Emphasis">Klebsiella</span></span> species (including <span class="Italics"><span class="Emphasis">K. </span></span><span class="Italics"><span class="Emphasis">pneumoniae</span></span>), <span class="Italics"><span class="Emphasis">Streptococcus</span></span> species (excluding enterococci), <span class="Italics"><span class="Emphasis">Bacteroides</span></span> species (excluding <span class="Italics"><span class="Emphasis">B. distasonis</span></span>, <span class="Italics"><span class="Emphasis">B. ovatus, B. thetaiotaomicron</span></span>) and <span class="Italics"><span class="Emphasis">Clostridium</span></span> species*. </p>
<p><span class="Bold"><span class="Emphasis">      Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span>    </span></span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus </span></span><span class="Italics"><span class="Emphasis">aureus</span></span>*. </p>
<p>* Efficacy for this organism in this organ system was studied in fewer than ten <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p>Specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to cefotetan.  Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. </p>
<p>In cases of confirmed or suspected gram-positive or gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or in patients with other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in which the causative organism has not been identified, it is possible to use cefotetan concomitantly with an aminoglycoside.  Cefotetan combinations with aminoglycosides have been shown to be synergistic <span class="Italics"><span class="Emphasis">in </span></span><span class="Italics"><span class="Emphasis">vitro</span></span> against many Enterobacteriaceae and also some other gram-negative bacteria.  The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patient's condition. </p>
<p><span class="Bold"><span class="Emphasis">      NOTE    </span></span>: Increases in serum creatinine have occurred when cefotetan was given alone.  If cefotetan and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may be potentiated.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ec3af4bd-c11a-4f02-9e87-b484e06024b4"></a><a name="section-4.2"></a><p></p>
<h2>Prophylaxis</h2>
<p class="First">The preoperative administration of cefotetan may reduce the incidence of certain <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infections</span> in patients undergoing surgical procedures that are classified as clean contaminated or potentially contaminated (e.g., cesarean section, abdominal or vaginal hysterectomy, transurethral surgery, biliary tract surgery, and gastrointestinal surgery). </p>
<p>If there are signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, specimens for culture should be obtained for identification of the causative organism so that appropriate therapeutic measures may be initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="cb728e24-0ed7-4e3f-a4fd-b8d5b3d1b27e"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cefotetan is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics and in those individuals who have experienced a cephalosporin associated <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="a28ba117-1bb6-40b1-ba61-870da1eb3f00"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">BEFORE THERAPY WITH CEFOTETAN IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFOTETAN, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS.  IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>.  IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFOTETAN OCCURS, DISCONTINUE THE DRUG.  SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. </p>
<p>AN IMMUNE MEDIATED <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span> HAS BEEN OBSERVED IN PATIENTS RECEIVING CEPHALOSPORIN CLASS ANTIBIOTICS.  SEVERE CASES OF <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span>, INCLUDING FATALITIES, HAVE BEEN REPORTED IN ASSOCIATION WITH THE ADMINISTRATION OF CEFOTETAN.  SUCH REPORTS ARE UNCOMMON.  THERE APPEARS TO BE AN INCREASED RISK OF DEVELOPING <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span> ON CEFOTETAN RELATIVE TO OTHER CEPHALOSPORINS OF AT LEAST 3 FOLD.  IF A PATIENT DEVELOPS <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">ANEMIA</span> ANYTIME WITHIN 2 TO 3 WEEKS SUBSEQUENT TO THE ADMINISTRATION OF CEFOTETAN, THE DIAGNOSIS OF A CEPHALOSPORIN ASSOCIATED <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">ANEMIA</span> SHOULD BE CONSIDERED AND THE DRUG STOPPED UNTIL THE ETIOLOGY IS DETERMINED WITH CERTAINTY.  BLOOD TRANSFUSIONS MAY BE CONSIDERED AS NEEDED (see <span class="Bold"><span class="Emphasis"><a href="#cb728e24-0ed7-4e3f-a4fd-b8d5b3d1b27e"> CONTRAINDICATIONS</a></span></span>). </p>
<p>PATIENTS WHO RECEIVE COURSES OF CEFOTETAN FOR TREATMENT OR PROPHYLAXIS OF <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> SHOULD HAVE PERIODIC MONITORING FOR SIGNS AND SYMPTOMS OF <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span> INCLUDING A MEASUREMENT OF HEMATOLOGICAL PARAMETERS WHERE APPROPRIATE. </p>
<p><span class="Italics"><span class="Emphasis">      Clostridium difficile     </span></span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including cefotetan, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics"><span class="Emphasis">C. difficile</span></span>.</p>
<p><span class="Italics"><span class="Emphasis">      C. difficile     </span></span>produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">C. difficile </span></span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics"><span class="Emphasis">C. difficile </span></span>may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics"><span class="Emphasis">C. difficile</span></span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p>In common with many other broad-spectrum antibiotics, cefotetan may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity and, possibly, subsequent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Those at increased risk include patients with renal or hepatobiliary impairment or poor nutritional state, the elderly, and patients with cancer.  <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored and exogenous vitamin K administered as indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="aea60c1b-f9c2-4e13-bacf-ed66e37c621e"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="e9d17b9a-df2e-48a3-bb64-8f7208b4496d"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing cefotetan in the absence of proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.<span class="Bold Italics"><span class="Emphasis"></span></span></p>
<p>As with other broad-spectrum antibiotics, prolonged use of cefotetan may result in overgrowth of nonsusceptible organisms.  Careful observation of the patient is essential.  If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> does occur during therapy, appropriate measures should be taken. </p>
<p>Cefotetan should be used with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f3afe201-6e8c-4e57-90c2-002e210a7f0a"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients<br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.  Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible.</p>
<p>Patients should be counseled that antibacterial drugs, including cefotetan, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When cefotetan is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefotetan or other antibacterial drugs in the future. </p>
<p>As with some other cephalosporins, a disulfiram-like reaction characterized by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> may occur when alcohol (beer, wine, etc.) is ingested within 72 hours after cefotetan administration.  Patients should be cautioned about the ingestion of alcoholic beverages following the administration of cefotetan.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fddc7baa-ecba-4447-8ed4-980023433e7a"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Increases in serum creatinine have occurred when cefotetan was given alone.  If cefotetan and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may be potentiated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ccb6a1ee-44b2-4bba-8738-3c5b86f5ba90"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions <br>
</h2>
<p class="First">The administration of cefotetan may result in a false positive reaction for glucose in the urine using Clinitest<span class="Sup">®‡</span>, Benedict's solution, or Fehling's solution.  It is recommended that glucose tests based on enzymatic glucose oxidase be used.  </p>
<p>As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffé reaction and produce false increases in the levels of creatinine reported.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fc315f40-59b1-43d9-8531-b2dd69590aa2"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">Although long-term studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic potential of cefotetan was found in standard laboratory tests. </p>
<p>Cefotetan has adverse affects on the testes of prepubertal rats.  Subcutaneous administration of 500 mg/kg/day (approximately 8 to 16 times the usual adult human dose) on days 6 to 35 of life (thought to be developmentally analogous to late childhood and prepuberty in humans) resulted in reduced testicular weight and seminiferous tubule degeneration in 10 of 10 animals.  Affected cells included spermatogonia and spermatocytes; Sertoli and Leydig cells were unaffected.  Incidence and severity of lesions were dose-dependant; at 120 mg/kg/day (approximately 2 to 4 times the usual human dose) only 1 of 10 treated animals was affected, and the degree of degeneration was mild. </p>
<p>Similar lesions have been observed in experiments of comparable design with other methylthiotetrazole-containing antibiotics and impaired fertility has been reported, particularly at high dose levels.  No testicular effects were observed in 7-week-old rats treated with up to 1000 mg/kg/day SC for 5 weeks, or in infant dogs (3 weeks old) that received up to 300 mg/kg/day IV for 5 weeks.  The relevance of these findings to humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e22ea916-2767-4f7b-88dc-4d1b9ed6fffd"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Emphasis">      Teratogenic Effects. Pregnancy Category B    </span></span></p>
<p>Reproduction studies have been performed in rats and monkeys at doses up to 20 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefotetan.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d2cef7f7-ce93-4885-939c-708c84071ff8"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">Cefotetan is excreted in human milk in very low concentrations.  Caution should be exercised when cefotetan is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b0e20049-0f87-487d-b1f8-fe0986eb22aa"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="df29aed1-0f8b-47f1-a4d3-e765678ee18d"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use<br>
</h2>
<p class="First">Of the 925 subjects who received cefotetan in clinical studies, 492 (53%) were 60 years and older, while 76 (8%) were 80 years and older.  No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <a href="#b58ac185-b10f-4d2d-bea0-83e1d8c4d5cf"> DOSAGE AND ADMINISTRATION, </a><span class="Bold Italics"><span class="Emphasis"><a href="#b58ac185-b10f-4d2d-bea0-83e1d8c4d5cf"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="dd00824e-c5d8-4a3a-b98d-b4a2a96433ca"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In clinical studies, the following adverse effects were considered related to cefotetan therapy.  Those appearing in italics have been reported during postmarketing experience. </p>
<p><span class="Bold"><span class="Emphasis">      Gastrointestinal:    </span></span> symptoms occurred in 1.5% of patients, the most frequent were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1 in 80) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1 in 700); <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. </span></span> Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment or surgical prophylaxis (see <span class="Bold"><span class="Emphasis"><a href="#a28ba117-1bb6-40b1-ba61-870da1eb3f00"> WARNINGS</a></span></span>). </p>
<p><span class="Bold"><span class="Emphasis">      Hematologic    </span></span>: laboratory abnormalities occurred in 1.4% of patients and included <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> (1 in 200), positive direct Coombs test (1 in 250), and <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> (1 in 300); <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span></span></span>, <span class="Italics"><span class="Emphasis">hemolytic</span></span><span class="Italics"><span class="Emphasis"> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></span></span>, <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span></span></span>, <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and </span></span><span class="Italics"><span class="Emphasis">prolonged</span></span><span class="Italics"><span class="Emphasis"> <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time with or without <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</span></span></p>
<p><span class="Bold"><span class="Emphasis">      Hepatic:    </span></span> enzyme elevations occurred in 1.2% of patients and included a rise in ALT (SGPT) (1 in 150), AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (1 in 300), alkaline phosphatase (1 in 700), and LDH (1 in 700). </p>
<p><span class="Bold"><span class="Emphasis">      <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:    </span></span> reactions were reported in 1.2% of patients and included <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1 in 150) and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> (1 in 700); <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</span></span></p>
<p><span class="Bold"><span class="Emphasis">      Local    </span></span>: effects were reported in less than 1% of patients and included <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> at the site of injection (1 in 300), and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (1 in 500). </p>
<p><span class="Bold"><span class="Emphasis">      Renal    </span></span>: <span class="Italics"><span class="Emphasis">Elevations in BUN and serum creatinine have been reported</span></span>. </p>
<p><span class="Bold"><span class="Emphasis">      Urogenital    </span></span>: <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> has rarely been reported. </span></span></p>
<p><span class="Bold"><span class="Emphasis">      Miscellaneous    </span></span>: <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></span></p>
<p>In addition to the adverse reactions listed above which have been observed in patients treated with cefotetan, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, elevated bilirubin, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. </p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, when the dosage was not reduced (see <span class="Bold"><span class="Emphasis"><a href="#b58ac185-b10f-4d2d-bea0-83e1d8c4d5cf"> DOSAGE AND ADMINISTRATION</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#f912695d-17be-426b-a289-d4ad2134e57d"> OVERDOSAGE</a></span></span>).  If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued.  Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="f912695d-17be-426b-a289-d4ad2134e57d"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Information on overdosage with cefotetan in humans is not available.  If overdosage should occur, it should be treated symptomatically and hemodialysis considered, particularly if renal function is compromised.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b58ac185-b10f-4d2d-bea0-83e1d8c4d5cf"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="c403b1d5-6bb7-43b3-8d62-6260815947d0"></a><a name="section-10.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">The usual adult dosage is 1 or 2 grams of Cefotetan for Injection, USP administered intravenously every 12 hours for 5 to 10 days.  Proper dosage and route of administration should be determined by the condition of the patient, severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organism.</p>
<table><tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top">
<span class="Bold"><span class="Emphasis">                 General Guidelines for Dosage of Cefotetan for Injection, USP</span></span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Daily Dose</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Frequency and Route</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">
<p class="First">Urinary Tract</p>
<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">1 to 4 grams</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">
<p class="First">500 mg every 12 hours IV</p>
<p>1 or 2 g every 24 hours IV </p>
<p>1 or 2 g every 12 hours IV</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3">
<p class="First">Skin &amp; Skin Structure </p>
<br><br><p>   Mild - Moderate<span class="Sup">a</span></p>
<br><br><br>
                Severe</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1">2 grams<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1">
<p class="First">2 g every 24 hours IV</p>
<p>1 g every 12 hours IV</p>
<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1"> 4 grams<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1"> 2 g every 12 hours IV <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Other Sites</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">2 to 4 grams</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">1 or 2 g every 12 hours IV</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Severe</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">4 grams</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">2 g every 12 hours IV</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Life-Threatening</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">6 grams<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">3 g every 12 hours IV</p></td>
</tr>
</tbody></table>
<br><p><span class="Italics"><span class="Emphasis"><span class="Sup">a</span></span></span><span class="Italics"><span class="Emphasis"> Klebsiella pneumoniae </span></span> skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> should be treated with 1 or 2 grams every 12 hours IV.</p>
<p><span class="Sup">b</span>Maximum daily dosage should not exceed 6 grams. </p>
<p>If <span class="Italics"><span class="Emphasis">Chlamydia trachomatis</span></span> is a suspected pathogen in gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, appropriate antichlamydial coverage should be added, since cefotetan has no activity against this organism.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="a90db40d-4e63-4633-880e-04bde36bd9b2"></a><a name="section-10.2"></a><p></p>
<h2>Prophylaxis</h2>
<p class="First">To prevent <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infection</span> in clean contaminated or potentially contaminated surgery in adults, the recommended dosage is 1 or 2 g of Cefotetan for Injection, USP administered once, intravenously, 30 to 60 minutes prior to surgery.  In patients undergoing cesarean section, the dose should be administered as soon as the umbilical cord is clamped.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c309e11c-1caf-4082-b35f-5a2bc21d4f02"></a><a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span><br>
</h2>
<p class="First">When renal function is impaired, a reduced dosage schedule must be employed.  The following dosage guidelines may be used.</p>
<table><tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">              DOSAGE GUIDELINES FOR PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span>            </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold"><span class="Emphasis">              Creatinine Clearance            </span></span></p>
<p><span class="Bold"><span class="Emphasis">              mL/min            </span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">              Dose            </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">              Frequency            </span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&gt; 30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Usual Recommended Dosage*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Every 12 hours</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10 to 30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Usual Recommended Dosage*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Every 24 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt; 10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Usual Recommended Dosage*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Every 48 hours</p></td>
</tr>
</tbody></table>
<p>* Dose determined by the type and severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organism.</p>
<p>Alternatively, the dosing interval may remain constant at 12 hour intervals, but the dose reduced to one-half the usual recommended dose for patients with a creatinine clearance of 10 to 30 mL/min, and one-quarter the usual recommended dose for patients with a creatinine clearance of less than 10 mL/min. </p>
<p>When only serum creatinine levels are available, creatinine clearance may be calculated from the following formula.  The serum creatinine level should represent a steady state of renal function. </p>
<p>Males:          <span class="Underline"><span class="Emphasis">       Weight (kg) x (140 - age)                 </span></span></p>
<p>                      72 x serum creatinine (mg/100 mL)</p>
<br><p>Females:   0.85 x value for males </p>
<p> </p>
<p>Cefotetan is dialyzable and it is recommended that for patients undergoing intermittent hemodialysis, one-quarter of the usual recommended dose be given every 24 hours on days between dialysis and one-half the usual recommended dose on the day of dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dbd11574-86ea-4f60-8e48-af7fecae4603"></a><a name="section-10.4"></a><p></p>
<h2>Preparation of Solution for Pharmacy Bulk Package for Intravenous Use - NOT FOR DIRECT INFUSION<br>
</h2>
<p class="First"> </p>
<p><span class="Bold"><span class="Emphasis">RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR IV INFUSION.</span></span></p>
<p>Reconstitute with Sterile Water for Injection; 5% Dextrose Injection; or 0.9% Sodium Chloride Injection.  Shake to dissolve and let stand until clear (see <span class="Bold"><span class="Emphasis"><a href="#bf9995c4-75a8-4025-855c-80aee004f295">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE</a></span></span>). </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Pharmacy</p>
<p>Bulk</p>
<p>Package bottle</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Amount of </p>
<p>Diluent to be</p>
<p>Added (mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Approximate Withdrawable </p>
<p>Vol (mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Approximate </p>
<p>Average Concentration(mg/mL)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">10 gram</p>
<p>Pharmacy Bulk</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">180</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">10 gram</p>
<p>Pharmacy Bulk</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">100</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">105</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">95</p></td>
</tr>
</tbody></table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ecd806bf-42ac-4525-b768-9a641d1abf39"></a><a name="section-10.5"></a><p></p>
<h2>Intravenous Administration<br>
</h2>
<p class="First">The intravenous route is preferable for patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, or other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or malignancy, particularly if <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present or impending.</p>
<p>For intermittent intravenous administration: Using an infusion system, a solution containing 1 gram or 2 grams cefotetan may be administered over 20 to 60 minutes through the tubing system by which the patient may be receiving other intravenous solutions.  Butterfly<span class="Sup">®</span> or scalp vein-type needles are preferred for this type of infusion.  However, during infusion of the solution containing Cefotetan for Injection, USP, it is advisable to discontinue temporarily the administration of other solutions at the same site.</p>
<p><span class="Bold"><span class="Emphasis">Note:</span></span> Solutions of Cefotetan for Injection, USP must not be admixed with solutions containing aminoglycosides.  If Cefotetan for Injection, USP and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection.  <span class="Bold"><span class="Emphasis">DO NOT ADD SUPLEMENTATARY MEDICATION.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bf9995c4-75a8-4025-855c-80aee004f295"></a><a name="section-11"></a><p></p>
<h1>DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE<br>
</h1>
<p class="First"> </p>
<p><span class="Bold"><span class="Emphasis">RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR IV INFUSION.</span></span></p>
<p>The closure may be penetrated only one time after reconstitution.  Use a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents.  The use of a syringe with a needle is not recommended as it may cause leakage.  Use of this product is restricted to a suitable work area, such as a laminar flow hood.</p>
<p>The withdrawal of container contents should be accomplished without delay.  However, should this not be possible, a maximum time of <span class="Bold"><span class="Emphasis">4 hours</span></span> from initial closure entry is permitted to complete fluid transfer operations.  This time limit should begin with the introduction of solvent or diluents into the Pharmacy Bulk Package.  Unused portions of solutions held longer than the recommended time periods should be discarded.</p>
<p>The aliquoting operation should be completed promptly after reconstitution of the contents (see Preparation of Solution).  Product dispensed in this manner should be administered within 24 hours, if stored at room temperature, 96 hours if stored under refrigeration (5°C) and 1 week if stored in the frozen state.  Any unused portion must be discarded within <span class="Bold"><span class="Emphasis">4 hours</span></span> after initial entry. </p>
<p><img alt="warning" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6b8667e-8bb6-ea58-a969-2f74458bc611&amp;name=cefotetan-for-injection,-usp-figure-2-cefotetan-box-warning.jpg"></p>
<span class="Bold"><span class="Emphasis"><br></span></span><p><span class="Bold"><span class="Emphasis">NOTE:</span></span> Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="e15fd4d7-3a95-4739-bd28-3e4e8ec276b5"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cefotetan for Injection,  USP, in the Pharmacy Bulk Package, is a dry, white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder supplied in a Pharmacy Bulk Package containing cefotetan disodium equivalent to 10 g cefotetan activity for intravenous administration as follows:</p>
<br><table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1"><span class="Bold"><span class="Emphasis">Product No. <br></span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1"><span class="Bold"><span class="Emphasis"> NDC No.<br></span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1"><span class="Bold"><span class="Emphasis"> Strength</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1"> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">309661</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">63323-396-61</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"> 10 grams</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Supplied in individual cartons containing one Pharmacy Bulk Package vial.</p></td>
</tr>
</tbody></table>
<p>Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].  <span class="Bold"><span class="Emphasis">PROTECT FROM LIGHT.</span></span></p>
<p>This container closure is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="a32662d9-9726-4e19-80df-d6b5eee35c47"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards. <span class="Underline"><span class="Emphasis">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically </span></span>- Third Edition.  Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA, December, 1993. </li>
<li>National Committee for Clinical Laboratory Standards. <span class="Underline"><span class="Emphasis">Performance Standards for Antimicrobial Disk Susceptibility Tests </span></span>- Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December 1993. </li>
<li>National Committee for Clinical Laboratory Standards. <span class="Underline"><span class="Emphasis">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria </span></span>- Third Edition. Approved Standard NCCLS Document M11-A3, Vol. 13, No. 26, NCCLS, Villanova, PA, December 1993.</li>
</ol>
<p class="First"><span class="Sup">‡</span>Clinitest<span class="Sup">®</span> is a registered trademark of Ames Division, Miles Laboratories, Inc.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="da70c0d0-e7f1-4901-b878-5842f31897b1"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:</p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6b8667e-8bb6-ea58-a969-2f74458bc611&amp;name=cefotetan-for-injection,-usp-figure-3-add_band_logo.jpg"> </p>
<br><p>451077G</p>
<p>Revised: November 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="f955f2e9-0d33-48b5-a2b6-862979e7ca95"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">      PACKAGE LABEL - PRINCIPAL DISPLAY - Cefotetan 10 grams Vial Label    </span></span></p>
<p><span class="Bold"><span class="Emphasis">      NDC    </span></span> 63323-396-61</p>
<p>309661</p>
<p><span class="Bold"><span class="Emphasis">      CEFOTETAN FOR INJECTION, USP</span></span></p>
<p>PHARMACY BULK PACKAGE  </p>
<p>NOT FOR DIRECT INFUSION</p>
<p><span class="Bold"><span class="Emphasis">10 grams per Pharmacy Bulk Package<br></span></span></p>
<p>For Intravenous Use</p>
<p>Caution - Not to be Dispensed as a Unit. </p>
<p>Rx only</p>
<br><p><img alt="309661-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6b8667e-8bb6-ea58-a969-2f74458bc611&amp;name=cefotetan-for-injection,-usp-figure-4-309661-vial.jpg"></p>
<br><br><br><br><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Cefotetan 10 grams Vial Carton Panel</span></span><p><span class="Bold"><span class="Emphasis"> NDC </span></span> 63323-396-61</p>
<p>309661</p>
<p><span class="Bold"><span class="Emphasis"> CEFOTETAN FOR INJECTION, USP</span></span></p>
<p>PHARMACY BULK PACKAGE  </p>
<p>NOT FOR DIRECT INFUSION</p>
<p><span class="Bold"><span class="Emphasis">10 grams per Pharmacy Bulk Package<br></span></span></p>
<p>For Intravenous Use</p>
<p>Caution - Not to be Dispensed as a Unit </p>
<p>Keep Top Closed </p>
<p>Rx only</p>
<p><span class="Bold"><span class="Emphasis">One</span></span> Pharmacy Bulk Package </p>
<br><p><img alt="309661-carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6b8667e-8bb6-ea58-a969-2f74458bc611&amp;name=cefotetan-for-injection,-usp-figure-5-309661-carton.jpg"></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOTETAN 		
					</strong><br><span class="contentTableReg">cefotetan disodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-396</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFOTETAN DISODIUM</strong> (CEFOTETAN) </td>
<td class="formItem">CEFOTETAN</td>
<td class="formItem">10 g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-396-61</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065375</td>
<td class="formItem">12/03/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Steri-Pharma LLC</td>
<td class="formItem"></td>
<td class="formItem">169663544</td>
<td class="formItem">MANUFACTURE(63323-396)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>86bb9239-35be-466d-bbc4-bed63507ea58</div>
<div>Set id: c6b8667e-8bb6-ea58-a969-2f74458bc611</div>
<div>Version: 3</div>
<div>Effective Time: 20120314</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
